PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15123680-0	2004	The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions.	ciprofibrate	73-85	apolipoprotein B	Mus musculus	95-111	
15123680-2	2004	Treatment of LDLR-deficient mice with ciprofibrate caused a marked decrease in plasma apoB-48-carrying IDL and LDL but at the same time caused a large accumulation of triglyceride-depleted apoB-100-carrying IDL and LDL, resulting in a significant increase in plasma cholesterol levels.	ciprofibrate	38-50	apolipoprotein B	Mus musculus	86-93	
15123680-2	2004	Treatment of LDLR-deficient mice with ciprofibrate caused a marked decrease in plasma apoB-48-carrying IDL and LDL but at the same time caused a large accumulation of triglyceride-depleted apoB-100-carrying IDL and LDL, resulting in a significant increase in plasma cholesterol levels.	ciprofibrate	38-50	apolipoprotein B	Mus musculus	189-197	
15123680-6	2004	After 150 days of treatment with ciprofibrate, consistent with the increased plasma accumulation of apoB-100-carrying IDL and LDL, the LDLR-deficient mice displayed severe atherosclerotic lesions in the aorta.	ciprofibrate	33-45	apolipoprotein B	Mus musculus	100-108	
15123680-7	2004	These findings demonstrate that ciprofibrate treatment decreases hepatic apoB mRNA editing and alters the pattern of hepatic lipoprotein secretion toward apoB-100-associated VLDL, changes that in turn lead to increased atherosclerosis.	ciprofibrate	32-44	apolipoprotein B	Mus musculus	73-77	
15123680-7	2004	These findings demonstrate that ciprofibrate treatment decreases hepatic apoB mRNA editing and alters the pattern of hepatic lipoprotein secretion toward apoB-100-associated VLDL, changes that in turn lead to increased atherosclerosis.	ciprofibrate	32-44	apolipoprotein B	Mus musculus	154-162	
14570884-8	2003	Restoration of SR-BI expression in ciprofibrate-treated apoE-deficient mice by recombinant adenoviral gene transfer abolishes the ciprofibrate-induced over accumulation of apoB-48-carrying remnants in the plasma.	ciprofibrate	35-47	apolipoprotein B	Mus musculus	172-179	
14570884-8	2003	Restoration of SR-BI expression in ciprofibrate-treated apoE-deficient mice by recombinant adenoviral gene transfer abolishes the ciprofibrate-induced over accumulation of apoB-48-carrying remnants in the plasma.	ciprofibrate	130-142	apolipoprotein B	Mus musculus	172-179	
12713444-9	2003	These results indicate that the ciprofibrate-induced accumulation of apoB-48-carrying remnants in apoE-deficient mice is caused by the inhibition of an as yet uncharacterized apoE-independent mechanism of removal of remnant from the circulation by the liver.	ciprofibrate	32-44	apolipoprotein B	Mus musculus	69-76